drugset
drugset / Trial / NCT04092751

Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects

NCT04092751 ↗

Phase 1 Completed 28 enrolled Scynexis, Inc. Clinical Network Services (CNS) Pty Ltd · collab
RandomizedCrossoverOpen-labelOther

Summary

This is an Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Effect of Oral Doses of SCY-078 (Ibrexafungerp) on the Pharmacokinetics of Pravastatin Administered Orally to Healthy Subjects

Timeline

Start
2019-11-22
Primary completion
2019-12-20
Completion
2019-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrexafungerp Small molecule 750 mg Oral
Subject Pravastatin Small molecule 20 mg Oral

Indications

No indication recorded.